Plant expression systems have been used for the past 26 years for the production of human or animal proteins of biopharmaceutical interest. Antigens, antibodies, and enzymes have been produced, and some of them commercialized using several plant expression platforms ^[@ref-1]^. While certain impediments remain such as community reluctance to accept transgenic products and the strict regulations for approval ^[@ref-2],\ [@ref-3]^, the FDA approval of ELELYSO ^®^ (alfa taliglucerase), a recombinant cerebrosidase for the treatment of Gaucher's disease, has motivated plant-based biopharmaceutical protein production. These methods are all the more attractive because they are cost-effective, safe and scalable ^[@ref-4]^.

After the arrival of Zika and chikungunya viruses to Latin American countries, they quickly became endemic diseases. They currently pose an acute and chronic burden for health systems and represent a diagnostic challenge in areas where those infections co-circulate with dengue and other febrile-illnesses ^[@ref-5],\ [@ref-6]^. Clinical diagnosis frequently is difficult given the similar clinical features with other viral infections such as dengue. However, the laboratory confirmation of Zika, dengue or chikungunya infection is important because each one has different implications for follow-up both in the short and long term. Diagnosis of acute, symptomatic infection is typically achieved through pathogen detection by virus isolation or qRT-PCR, Serology may be helpful later in the acute illness, but requires convalescent sampling in many cases and comes at a significant cost for healthcare systems. For this reason, confirmation is not recommended for the general population and has been restricted to specific cases. On the other hand, prevention of infection has been in the spotlight for policy makers. There are Zika and chikungunya vaccines under development, but current vaccine production is compromised by reduced capacity of vaccine manufacturers and substantial unmet needs for investment ^[@ref-7]^.

Developing countries have been the most affected worldwide with these vector-borne diseases, and plant-based expression platforms have been proposed as a biotechnological tool to address the vaccine development challenge ^[@ref-8]^. Plants could be used as bio-factories for the production of antigens, for both rapid diagnostic test design and vaccine production. Plant platforms operate at a small fraction of the cost (0.1% to 10%) of other expression systems like bacteria or mammalian cells ^[@ref-9]^. Additionally, it has higher protein yield, lower contamination risk, lower storage cost, ability to assemble complex proteins with minor glycosylation differences, as well as high product quality, safety, and scalability ^[@ref-9],\ [@ref-10]^.

Although post-translational modifications have been a concerning issue, plant-derived vaccines can elicit protective immune responses ^[@ref-11],\ [@ref-12]^. Glycoengineering allows modification of protein glycosylation patterns in order to improve immunogenicity. Additionally, plant derived polysaccharides have been proposed as adjuvants and vehicles, further highlighting plants as a biofactory for antigen production ^[@ref-10],\ [@ref-11]^. Finally, viral antigens produced in plants have been used to target other arboviruses like the West Nile virus ^[@ref-11]^.

In this context, a research agenda to assess the production of pharmaceutical proteins through plant molecular farming seems like a possible scenario to deal with current arboviruses epidemics. At first, candidate proteins should be defined. These proteins should be highly conserved and highly immunogenic. Importantly, antigen similarity between flaviviruses like dengue, yellow fever and Zika viruses has limited target antigen selection, for both vaccine and diagnostic test design for Zika, because of cross-reactivity and the risk of antibody dependent enhancement of infection ^[@ref-13]^. Regarding chikungunya virus, the envelope glycoprotein E2 has been studied for both vaccine and rapid diagnostic test design, and even the use of plant produced virus like particles has been proposed as candidate for vaccine production ^[@ref-14]^ ( [Table 1](#T1){ref-type="table"}).

###### Possible protein targets for expression in plant systems for chikungunya vaccine or rapid diagnostic test developing.

  ---------------------------------------------------------------------------------------------------------------------------------------------------
  Target protein   Protein\                   Rapid\            Vaccine\      Advantages              Disadvantages           Reference
                   characteristics            diagnostic test   development                                                   
  ---------------- -------------------------- ----------------- ------------- ----------------------- ----------------------- -----------------------
  E1               Protein type: Surface\     X                 X             Produce neutralizing\   Plant glycosilation\    [@ref-15]
                   glycoprotein; Function:\                                   antibodies response     pattern could modify\   
                   Virus entry                                                                        immune response\*       

  E2               Protein type: Surface\     X                 X             Produce neutralizing\   Plant glycosilation\    [@ref-16], [@ref-17]
                   glycoprotein; Function:\                                   antibodies response     pattern could modify\   
                   Viral attachment                                                                   immune response\*       

  nsP2             Cysteine protease with\                      X             Could be used\          Reduced immune\         [@ref-18]
                   two separate domains\                                      as adjuvant for\        response induction.\    
                   with helicase and\                                         glycoproteins based\    Greater genetic\        
                   protease activity                                          vaccines                diversity               

  E3-E2-6K-E1      Envelope poly-proteins                       X             Produce neutralizing\   Large cloning\          [@ref-19]
                                                                              antibodies              vector size, complex\   
                                                                                                      assembly and\           
                                                                                                      purification\*          

  C-E3-E2-6K-E1    Virus like particles                         X             High\                   Large cloning\          [@ref-20]-- [@ref-22]
                                                                              immunogenicity.\        vector size, complex\   
                                                                              Produce neutralizing\   assembly and\           
                                                                              antibodies that have\   purification\*          
                                                                              proved protection\                              
                                                                              against wild-type\                              
                                                                              virus                                           

  Neutralizing\    IgG monoclonal\                              X             Could be used\          Difficult production\   [@ref-23], [@ref-24]
  Monoclonal\      antibodies against E1,\                                    in passive\             in commercial scale,\   
  Antibodies       E2 or C                                                    immunization            complex cloning\        
                                                                                                      vector assembly         
  ---------------------------------------------------------------------------------------------------------------------------------------------------

\*Plant glycosylation could both enhance or limit immune response.

In addition, the plant expression system should be carefully selected. It is important to note that not all plants can be transformed, and phenolic compounds produced by plants and some of its secondary metabolites could make the purification of the desired protein difficult. Furthermore, the risk of contamination of other crops by the spread of transgenic pollen must be monitored according to the transformation method and plant species used for it. Transformation protocols in *Nicotiana benthamiana, N. tabacum,* and *Solanum tuberosum* have been used most commonly ^[@ref-9]^.

Because of its scalability, efficiency and effectiveness, transformation using *A. tumefaciens* has been the preferred method for biopharmaceutical protein production. This method does not require special equipment like the gene gun, it allows a more precise and selective transgene insertion, and results in lower tissue damage and thus higher available biomass for protein production. Using this method both transient and stable transformation is obtained. In recent years, the method of agroinfiltration for transient plant transformation is preferred because of its potential to be systematized and provide an adequate yield of protein in the short-term ^[@ref-4],\ [@ref-9]^.

In conclusion, plant expression systems of heterologous proteins are a feasible strategy for vaccine development and rapid diagnostic kit design. Additionally, it could enable developing countries to address the challenge of current arboviruses epidemics, both in improving diagnostics as well as increasing primary prevention. The development of a molecular plant farming research agenda seems as a worthy solution to empower research in developing countries. It will permit every country to take advantage of its own natural resources in an individualized manner to deal with its own epidemiologic challenges.

We thank Dr. Matthew Collins (Division of Infectious Diseases, University of North Carolina) for assisting us with language style.
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The authors discuss an interesting concept of using plants as vehicles for the production of vaccines and pharmaceutically important proteins. Although it is a promising field with some successful examples already existing, I get the impression from the text that it may lead to a quick solution for the vaccine development targeting the current Zika and chikungunya outbreaks. However, given the time for the development and testing needed before such a vaccine could be administered to a larger population I cannot foresee that this will happen in the near future. Maybe this can be rephrased to reflect this. Furthermore, the skeptical or negative opinion against transgenic crops existing in many countries may also affect the medical substances in question here, especially if targeting edible vaccines. As this may be a larger obstacle than the actual technological challenges, this could have been discussed further.
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Dr Ospina gives us a clear insight on the plant platforms for producing antigens for both diagnosis and for vaccine development in Chikungunya and Zika. It enables a large scale production with lower costs and should be evaluated in countries with resource-limiting conditions.
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